7 completed, 6 unknown, 5 recruiting, 4 withdrawn. 26 Phase 2, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 26 | Completed 7, Unknown 6, Recruiting 5, Withdrawn 4, Not yet recruiting 2, Active not recruiting 1, Terminated 1 |
| Phase 1 | 3 | Unknown 2, Completed 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Thymalfasin: new trials by email Literature Review of Thymalfasin trials Research Report on Thymalfasin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thymalfasin Combined With Chemotherapy and Immunotherapy in TNBC Neoadjuvant Treatment Thymalfasin - Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Fudan University | 572 | 2026-11-08 | 2026-10-20 |
| Study of Adebrelimab Combined With Thymalfasin and Chemotherapy for Neoadjuvant Treatment of Esophageal Cancer Adebrelimab, Thymalfasin, Chemotherapy - Esophageal Cancer | Phase 2 | Not yet recruiting | The Affiliated Hospital of Putian University | 31 | 2026-08-30 | 2026-08-21 |
| Thymosin-α1 for Recurrent Implantation Failure Thymosin Alpha1, Placebo Control - Recurrent Implantation Faliure | Phase 2 / Phase 3 | Recruiting | Fakih IVF Fertility Center | 136 | 2026-02-11 | 2026-10-15 |
| "Thymalfasin Immunotherapy Study with Triple Regimen in Advanced MSS/pMMR Colorectal Cancer" Thymalfasin (Thymosin alpha 1, Ta1), Regorafenib (BAY 73-4506), Tislelizumab (BGB-A317) - MCRC | Phase 2 | Recruiting | Beijing Friendship Hospital | 52 | 2025-02-11 | 2025-02-17 |
| Thymalfasin and Recombinant Human IL-2 Injections in Treating Lymphocytopenia for Patients With Malignant Hematological Tumors Thymalfasin for injection in combination with Recombinant Human Interleukin-2 Injections, Recombinant Human Interleukin-2 Injections - Hematological Malignancy, Lymphocytopenia | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 50 | 2024-09-01 | 2024-09-19 |
| Efficacy and Safety of Anti-PD-1, Thymalfasin, and SOX in Neoadjuvant Treatment of cStage III Gastric/Gastroesophageal Junction Adenocarcinoma Serplulimab, thymalfasin, Oxaliplatin - Gastric Cancer, Esophagogastric Junction Adenocarcinoma | Phase 2 | Recruiting | Zekuan Xu | 30 | 2024-06-14 | 2026-03-03 |
| Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer capecitabine, tislelizumab, thymalfasin - Locally Advanced Rectal Cancer | Phase 2 | Active not recruiting | Beijing Friendship Hospital | 20 | 2024-01-03 | 2025-04-02 |
| The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC definitive radiotherapy, induction chemo-immunotherapy, concurrent chemotherapy - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 114 | 2023-07-25 | 2026-08-03 |
| Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody - Melanoma, Immune-related Adverse Event | Phase 2 | Recruiting | Sun Yat-sen University | 55 | 2023-05-30 | 2026-06-12 |
| Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor - Advanced Solid Tumor, Refractory Tumor | Phase 2 | Unknown | Second Affiliated Hospital of Soochow University | 60 | 2023-04-01 | 2023-03-30 |
| Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients Thymalfasin - COVID-19 | Phase 2 | Completed | William B. Ershler, MD | 189 | 2021-01-12 | 2026-04-21 |
| Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection Thymalfasin - Covid19 | Phase 2 | Terminated | Rhode Island Hospital | 56 | 2020-09-10 | 2023-02-14 |
| Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer Concurrent chemotherapy, split-course radiotherapy, thymosin alpha 1 - Non-small Cell Lung Cancer | Phase 2 | Completed | Sun Yat-sen University | 69 | 2018-08-09 | 2022-01-03 |
| First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy Thymalfasin (Thymosin alpha 1, Ta1), SoC (tyrosine kinase inhibitor) - EGFR Mutation Positive Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Unknown | SciClone Pharmaceuticals | 188 | 2016-10-01 | 2016-09-19 |
| Thymosin Alpha 1 Plus Maintenance Therapy With the Standard of Care (SoC) in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC), EGFR Wild Type Thymalfasin (Thymosin alpha 1, Ta1), SoC (chemotherapy and platinum agent) - Non-Small Cell Lung Cancer | Phase 2 | Unknown | SciClone Pharmaceuticals | 140 | 2016-09-01 | 2016-09-19 |
| Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy TKI, Thoracic Hypofractionated Radiotherapy, Thymosin Alpha 1 - Lung Adenocarcinoma | Phase 2 | Unknown | First People's Hospital of Hangzhou | 46 | 2016-05-01 | 2016-11-25 |
| Abscopal Effect for Metastatic Non-small Cell Lung Cancer. Radiotherapy, Thymalfasin - Non-small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer | Phase 2 | Withdrawn | Zhejiang Provincial People's Hospital | 2016-01-01 | 2019-03-26 | |
| SBRT Combined With Thymalfasin for Metastatic Esophageal Cancer Stereotactic Body Radiation Therapy, Thymalfasin - Esophageal Cancer, Metastatic Esophageal Cancer | Phase 2 | Unknown | Hangzhou Cancer Hospital | 29 | 2016-01-01 | 2017-11-28 |
| Abscopal Effect for Metastatic Colorectal Cancer Radiation therapy, Thymalfasin - Colorectal Cancer, Metastatic Colorectal Cancer | Phase 2 | Withdrawn | Zhejiang Provincial People's Hospital | 2015-09-01 | 2023-09-21 | |
| Abscopal Effect for Metastatic Small Cell Lung Cancer Radiotherapy, Thymalfasin - Small Cell Lung Cancer, Radiotherapy | Phase 2 | Withdrawn | Zhejiang Provincial People's Hospital | 2015-09-01 | 2019-03-21 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (5) · Breast Neoplasms (2) · COVID-19 (2) · Esophageal Neoplasms (2) · Hematologic Neoplasms (2) · Lymphopenia (2) · Melanoma (2) · Adenocarcinoma of Lung (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Hepatitis B, Chronic (1) · Kidney Failure, Chronic (1) · Neoplasms (1) · Small Cell Lung Carcinoma (1) · Stomach Neoplasms (1)
SciClone Pharmaceuticals (3) · Sun Yat-sen University (3) · Zhejiang Provincial People's Hospital (3) · Beijing Friendship Hospital (2) · sigma-tau i.f.r. S.p.A. (2) · Fakih IVF Fertility Center (1) · First People's Hospital of Hangzhou (1) · Fudan University (1) · Hangzhou Cancer Hospital (1) · Inge Marie Svane (1) · Replicor Inc. (1) · Rhode Island Hospital (1) · Second Affiliated Hospital of Soochow University (1) · The Affiliated Hospital of Putian University (1) · The First Affiliated Hospital of Xiamen University (1)
China (11) · Italy (5) · United States (3) · Bangladesh (1) · Denmark (1) · France (1) · Germany (1) · Hungary (1) · Poland (1) · Portugal (1) · Spain (1) · Switzerland (1) · United Arab Emirates (1)
Shixiu Wu, MD (2) · Yongshi Jia, MD (2) · Agostino Naso, MD (1) · Andrea Velardi, Prof (1) · Dandan Li, PhD (1) · Eleftherios Mylonakis, MD PhD FIDSA (1) · Hui Liu, Professor (1) · Inge Marie Svane, prof MD (1) · Jingjing Zhao, PhD (1) · Mamun Al-Mahtab, MD (1) · Michael Fakih, MD (1) · Penghui Zhou, PhD (1) · Prof. Paolo Marchetti, MD (1) · Roberto Camerini, MD (1) · Shuqiang Wu, MD (1)
PMID 10741392, PMID 16741252, PMID 20194853, PMID 23045967, PMID 26096650, PMID 27257978, PMID 31323705, PMID 35870709, PMID 35874780, PMID 36056913, PMID 38458816, PMID 3998766, PMID 41749205